Best Agrolife Limited

Best Agrolife reported a challenging Q2 FY26, with revenue declining 30.8% YoY to ₹516.8 crores from ₹746.6 crores in Q2 FY25. This was primarily attributed to severe unseasonal rains and floods during the Khareef season, which caused significant crop damage and weakened agrochemical demand. EBITDA fell 47.3% YoY to ₹77.5 crores, and PAT decreased 59.6% YoY to ₹38.3 crores, with margins compressing to 15% and 7.4% respectively. The company noted that the Khareef season highlighted Indian farmers' heavy dependence on monsoons, with several key regions experiencing floods and delayed harvesting.

In response to the challenging environment, Best Agrolife implemented strategic shifts focusing on operational efficiency and financial discipline. The company consciously optimized inventory, streamlining channels, and aligning production with actual market demand to reduce working capital stress. Inventory levels decreased by ₹207 crore (24% YoY) from H1 FY25 to H1 FY26, and OPEX was reduced by 13% compared to Q2 FY25 and 11% compared to H1 FY25. A revised sales return policy and reduced pre-season order placement strategy are expected to lead to significantly lower sales returns in Q3 FY26 compared to previous years.

A key strength highlighted was the growing portfolio of patented products, which now contribute to more than half of the brand portfolio. This shift is enhancing brand value and is expected to improve the margin profile and competitive advantage. Management noted positive farmer feedback on products like Bestman, Fetagen, and SHOT DOWN, with Bestman being particularly effective against thrips and mites. Despite lower overall revenue, the quality of the revenue mix has improved due to the increased sales of patented products.

Best Agrolife is actively expanding its international footprint, particularly in Africa and through its China subsidiary. The company expects to achieve $1 million in business from a single African customer and $6 million to $8 million in revenue from its China subsidiary by the end of FY26. Efforts are underway for product registrations in Mauritius, Sri Lanka, and Vietnam, with active ingredients and formulations moving through approval processes in Taiwan, Mexico, Thailand, and other key markets. The company also emphasized its R&D focus, having added four new patents in H1, including a novel nano-urea footprint, and is exploring AI adoption in its operations.

The company's CAPEX plans, specifically for the Gajraula plant, have been delayed by 3-6 months. This decision was made to prioritize business stabilization and financial belt-tightening amidst the tough monsoon season, rather than immediately investing in new CAPEX. On the debt front, Best Agrolife has reduced its debt by ₹150 crores over the last 1.5 years. The cost of debt is approximately 9.5%, and the company's credit rating is BBB. Management confirmed no foreign currency or term loans, indicating a focus on working capital management.

Management expressed cautious optimism for the Rabi season, expecting volume growth to recover due to improved farmer sentiments, full reservoirs, and favorable soil moisture levels. They anticipate stronger demand for wheat and potato-related crop solutions. For the full fiscal year FY26, the company aims for an approximate turnover of ₹1,500 crore and an EBITDA margin of 13-14%. The focus for H2 FY26 will be on returning to profitability in Q3 and Q4, driven by operational efficiency, innovation, and reduced sales returns.